Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Rare Diseases: Growing Understanding Will Unlock Accelerated Approval, FDA Says

Executive Summary

US FDA officials say they need knowledge of the disease to have the confidence to use accelerated approval.


Related Content

Common Treatment May Be Removed In Alcoholic Hepatitis Trials
Moscicki's Move From FDA To PhRMA About 'Best' Use Of Leadership Skills
FDA Orphan Disease Clinical Trial Grants Aim To Reduce Financial Risk
How Accelerated Approval Works – And How It Doesn't
Duchenne Muscular Dystrophy: Second Product Isn't The Charm
Biomarkers In Orphan Studies Still Need Past Experience, FDA Says
Rare Diseases Need Ongoing Natural History Studies To Speed Trials, FDA Says
Orphan Products Mostly Approved With Regulatory Flexibility, NORD "Catalog" Finds


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts